Background Whilst apps and e-tools have tremendous potential as low-cost, scalable mental health intervention and prevention tools, it is essential that consumers and health professionals have a means by which to evaluate their quality and safety. Objective This study aimed to: 1) adapt the original Mobile App Rating Scale (MARS) in order to be appropriate for the evaluation of both mobile phone applications as well as e-tools; 2) test the reliability of the revised scale; and 3) develop a quality assurance protocol for identifying and rating new apps and e-tools to determine appropriateness for use in clinical practice. Methods The MARS was adapted to include items specific to health-related apps and e-tools, such as the availability of resources, strategies for self-management, and quality information. The 41 apps and e-tools in the standard youth configuration of the InnoWell Platform, a digital tool designed to support or enhance mental health service delivery, were independently rated by two expert raters using the A-MARS. Cronbach's alpha was used to calculate the internal consistency and interclass correlation coefficients were used to calculate interrater reliability. Results The A-MARS was shown to be a reliable scale with acceptable to excellent internal consistency and moderate to excellent interrater reliability across the subscales. Given the ever-increasing number of health information technologies on the market, a protocol to identify and rate new apps and e-tools for potential clinical use is presented. Conclusions Whilst the A-MARS is a useful tool to guide health professionals as they explore available apps and e-tools for potential clinical use, the training, time, and skill required to use it effectively may be prohibitive. As such, health professionals and services are likely to benefit from including a digital navigator as part of the care team to assist in selecting and rating apps and e-tools, increasing the usability of the data, and technology troubleshooting. When selecting, evaluating and/or recommending apps and e-tools to consumers, it is important to consider: 1) the availability of explicit strategies to set, monitor and review SMART goals; 2) the accessibility of credible, user friendly information and resources from reputable sources; 3) evidence of effectiveness; and 4) interoperability with other health information technologies.

Abstract-The exponential growth of the Routing Information Base (RIB) of the Internet's Default-Free Zone (DFZ) routers has raised concerns about non-scalability of the current Internet's routing architecture. The main reason is that Internet addresses currently carry information about both the identity and location (physical connection point) of devices connected to the Internet. The Locator/ID Separation Protocol (LISP) has been introduced to potentially remedy this non-scalability by splitting the location and identity of devices. In this paper, we present the architecture of a deployed testbed that is multihomed using LISP. We investigate LISP performance as a multihoming solution in terms of load balancing and traffic routing in the case of link failures.

Australia1 Arterial blood pressure, heart rate and cardiac contractility were measured in pentobarbitoneanaesthetized mongrel dogs and in conscious, instrumented dogs. 2 In anaesthetized dogs (n = 5), dose-response curves were obtained by intravenous infusion of increasing doses of dopexamine (5-20 fg kg-' min -). Infusions were administered three times to each animal to determine whether the responses were reproducible. Dopexamine increased heart rate and myocardial contractility and decreased blood pressure. The dose-response curves for dopexamine did not differ significantly over time. 3 In a second group of dogs (n = 6), dose-response curves (5-20 mg kg' min') were obtained as above and repeated after the administration of amitriptyline (2 mg kg-', i.v.). Amitriptyline caused a non-significant reduction in the inotropic and chronotropic responses to dopexamine.4 Control dose-response curves for dopexamine (5-50f.gkg-'min-1) were similarly obtained in a third group of dogs (n = 6), and repeated after bilateral vagotomy and sympathetic denervation of the heart. In these animals, a third dose-response curve for dopexamine was obtained after the administration of ICI 118551 (0.2 mg kg-', followed by 0.2mg kg-' h-'). The chronotropic response to dopexamine was significantly reduced after cardiac denervation. There was a small, non-significant reduction in the inotropic and depressor responses after denervation. Administration of ICI 115881 significantly reduced both the inotropic and chronotropic response to dopexamine and caused a non-significant reduction in the depressor response.5 The effect of raclopride (0.2 pmol kg-', p.o.) was investigated by comparison of the dose-response curves for dopexamine in a control group of dogs (n = 6) to those obtained in dogs which had been pretreated with raclopride (n = 5). Raclopride had no significant effect on the cardiovascular responses to dopexamine. 6 In conscious, instrumented dogs (n = 5), pretreated with raclopride, dose-related positive inotropic and chronotropic and depressor responses to dopexamine infusions were recorded. The chronotropic responses in conscious animals were significantly greater than those in the anaesthetized animals. 7 The results of this study indicate that both the positive inotropic and chronotropic actions of dopamine are due to a combination of direct, P2-adrenoceptor-mediated effects and the baroreceptor reflex response to the depressor action of the drug.